qwo228qg

Property	Value
?:abstract	Background: Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPLs) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-ß2GPI), and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-ß2GPI antibodies was not reported. Objective: To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-ß2GPI antibodies. Methods: ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events. Results: Anti-ß2GPI IgG/IgA/IgM was the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM was detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of ß2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-ß2GPI nor with thrombosis. Conclusions: aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against ß2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/qwo228qg_hasAnnotation_C0007188> <https://research.tib.eu/covid-19/entity/qwo228qg_hasAnnotation_C0031623> <https://research.tib.eu/covid-19/entity/qwo228qg_hasAnnotation_C0040053> <https://research.tib.eu/covid-19/entity/qwo228qg_hasAnnotation_C0087086> <https://research.tib.eu/covid-19/entity/qwo228qg_hasAnnotation_C0349410> <https://research.tib.eu/covid-19/entity/qwo228qg_hasAnnotation_C1706005>
?:creator	<https://research.tib.eu/covid-19/entity/Borghi%2C_Maria_Orietta%3B_Beltagy%2C_Asmaa%3B_Garrafa%2C_Emirena%3B_Curreli%2C_Daniele%3B_Cecchini%2C_Germana%3B_Bodio%2C_Caterina%3B_Grossi%2C_Claudia%3B_Blengino%2C_Simonetta%3B_Tincani%2C_Angela%3B_Franceschini%2C_Franco%3B_Andreoli%2C_Laura%3B_Lazzaroni%2C_Maria_Grazia%3B_Piantoni%2C_Silvia%3B_Masneri%2C_Stefania%3B_Crisafulli%2C_Francesca%3B_Brugnoni%2C_Duilio%3B_Muiesan%2C_Maria_Lorenza%3B_Salvetti%2C_Massimo%3B_Parati%2C_Gianfranco%3B_Torresani%2C_Erminio%3B_Mahler%2C_Michael%3B_Heilbron%2C_Francesca%3B_Pregnolato%2C_Francesca%3B_Pengo%2C_Martino%3B_Tedesco%2C_Francesco%3B_Pozzi%2C_Nicola%3B_Meroni%2C_Pier_Luigi>
?:journal	Front_Immunol
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/qwo228qg_HAS_C0003241_ASSOCIATED_WITH_C0085278> <https://research.tib.eu/covid-19/entity/qwo228qg_HAS_C0005779_CAUSES_C0349410> <https://research.tib.eu/covid-19/entity/qwo228qg_HAS_C0053358_ASSOCIATED_WITH_C0085278> <https://research.tib.eu/covid-19/entity/qwo228qg_HAS_C0162595_ASSOCIATED_WITH_C0085278> <https://research.tib.eu/covid-19/entity/qwo228qg_HAS_C0162595_ASSOCIATED_WITH_C5203670>
?:source	WHO
?:title	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#908875
?:year	2020

Property

Value

?:abstract

Background: Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPLs) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-ß2GPI), and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-ß2GPI antibodies was not reported. Objective: To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-ß2GPI antibodies. Methods: ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events. Results: Anti-ß2GPI IgG/IgA/IgM was the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM was detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of ß2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-ß2GPI nor with thrombosis. Conclusions: aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against ß2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.

is ?:annotates of